AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00129467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention.
Trial: NCT00189501
Drug: Sensipar®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026220
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01026220
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02027753
Drug: Sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT01573156
Drug: Light activated WST11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
Trial: NCT01009086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT00003552
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01496755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single/multiple doses
Trial: NCT01496755
Drug: RG7667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single/multiple ascending doses
Trial: NCT02193113
Drug: KVD001 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel plasma kallikrein inhibitor
Trial: NCT01229449
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
Trial: NCT01229449
Drug: Ibuprofen/acetaminophen (higher dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
Trial: NCT01229449
Drug: Nurofen Plus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
Trial: NCT01229449
Drug: Panadeine® Extra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
Trial: NCT01229449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets, single dose taken orally with 300 ml water
Trial: NCT04117698
Drug: Antitubercular treatment (RIFATER ©)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group.
Trial: NCT04117698
Drug: RIFINAH ©
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIFINAH ©
Trial: NCT01789606
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Trial: NCT03230682
Drug: antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
Trial: NCT02128074
Drug: KRX-0502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g tablets of KRX-0502
Trial: NCT01204762
Drug: pegIFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
Trial: NCT01204762
Drug: pegIFNα-2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
Trial: NCT03574402
Drug: AZD3759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg PO BID on days 1-28. 28 days as one cycle.
Trial: NCT02264028
Drug: [14C]-DK-AH 269 CL, solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264028
Drug: [14C]-DK-AH 269 CL, drinking solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02169856
Drug: Drug: Inj. Ketorolac 30 mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
Trial: NCT02169856
Drug: Inj. Zantac 50mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Trial: NCT00293020
Drug: BEMA Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
Trial: NCT01147848
Drug: Placebo (1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder inhaled orally once daily for 24 weeks
Trial: NCT01147848
Drug: Placebo (2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder inhaled orally twice daily for 24 weeks
Trial: NCT00685737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT03783182
Drug: 10% glucose solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
Trial: NCT04506034
Drug: IV saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received i.v. saline infusion.
Trial: NCT02267681
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl for sedation/analgesia
Trial: NCT03713957
Drug: GRF6021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF6021 for IV infusion
Trial: NCT05865431
Drug: Zinc Oxide and Avobenzone
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
Trial: NCT01554995
Drug: LCB01-0371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
Trial: NCT03549715
Drug: MVAC Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1
Trial: NCT04650555
Drug: BIO 300 Oral Powder
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorphous solid dispersion of genistein milled into a powder
Trial: NCT00220298
Drug: Testosterone undecanoate (TU) - NebidoTM
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
Trial: NCT02248298
Drug: 3h-AFL-PDT
RxNorm normalized name: (1,2,6,7-3H)-testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
Trial: NCT02248298
Drug: 3hr-MAL-PDT
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
Trial: NCT01978613
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for one-daily oral administration.
Trial: NCT01881126
Drug: travatan 0.004%
RxNorm normalized name: Travatan 0.004% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travatan 0.004% administered to both eyes once daily for 12 weeks.
Trial: NCT01791933
Drug: herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
Trial: NCT03536806
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
Trial: NCT02471196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: NCT03334435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03273634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02291731
Drug: Continuous use of topical autologous serum
RxNorm normalized name: Ivy Dry Super Continuous Spray Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
Trial: NCT00599612
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
Trial: NCT02185196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Trial: NCT02251093
Drug: Lcr Regenerans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
Trial: NCT01439373
Drug: GSK2336805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Investigational Drug
Trial: NCT01439373
Drug: GSK2336805 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Investigational Drug
Trial: NCT01011829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
Trial: NCT02708355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01959243
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution to be applied as directed.
Trial: NCT03549650
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.
Trial: NCT03372200
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosing for 14 weeks
Trial: NCT00334711
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01792401
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01792401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01429480
Drug: Patient controlled analgesia
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00796302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
Trial: NCT01078168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00812565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% isotonic sodium chloride solution.
Trial: NCT04591847
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drugs 1 tab oral weekly
Trial: NCT03281083
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01748825
Drug: MK-1775 (AZD1775)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
Trial: NCT04487652
Drug: with CoQ10 spray application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
Trial: NCT04487652
Drug: with placebo spray application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
Trial: NCT01624675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching with risperidone orally up to 8 weeks.
Trial: NCT03311373
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
Trial: NCT03311373
Drug: Regimen D
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
Trial: NCT04594928
Drug: GLPG3667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3667 capsules
Trial: NCT00003214
Drug: in vitro sensitivity-directed chemotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04594928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02301624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
Trial: NCT00895310
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
Trial: NCT02772627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets; oral route.
Trial: NCT04322682
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Trial: NCT00605280
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinicians decision to use optional laser therapy.
Trial: NCT01775904
Drug: LY2886721 in a Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00619307
Drug: Rebif New Formulation + prophylactic Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
Trial: NCT01662310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
Trial: NCT02446301
Drug: Bain®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine HCl 20mg, IM injection
Trial: NCT02446301
Drug: SDE
RxNorm normalized name: Spasdel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
Trial: NCT01826474
Drug: PRO045, 3.0 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01826474
Drug: PRO045, 6.0 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01826474
Drug: PRO045, 9.0 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01826474
Drug: PRO045, selected dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT00884221
Drug: Highly purified menotrophin
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Trial: NCT00619307
Drug: Rebif New Formulation + ibuprofen PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
Trial: NCT00913926
Drug: E2/LNG oral (Wellnara, BAY86-5029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life treatment receiving Wellnara according to local drug information.
Trial: NCT00711789
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
Trial: NCT00020878
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
Trial: NCT01880723
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulized 3mL normal saline) using a Power Neb2 nebulizer